2017. ISPOR European Congress – Using convergent mixed methods to evaluate treatment risks and benefits in rare disease: An example from a Phase II registration trial in metastatic Merkel Cell Carcinoma

Bharmal M, Guillemin I, Marrel A, Lambert J, Arnould B, Fofana F, et al. Using convergent mixed methods to evaluate treatment risks and benefits in rare disease: An example from a Phase II registration trial in metastatic Merkel Cell Carcinoma. Value Health. 2017 Oct-Nov;20(9):A731. Presented at: ISPOR 20th European Meeting: November 4-8, 2017; Glasgow, UK.